Tuhura Biosciences Inc HURA

$1.65 -0.07 (-4.07%)

Valuation

Market cap
109,610,000
Revenue TTM
$0
Net income TTM
$-30,050,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.47

Trading

Volume
569,800
Avg volume
284,942
Day's range
$1.65 – $1.82
Shares out
63,727,000
Stochastic %K
1%
Beta
-0.23
Analysts
Strong Buy
Price target
$7.87

Price

Company profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 adminis...

Show more

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
813 875 6600
Website
https://www.tuhurabio.com
Address
10500 University Center Drive, Suite 110, Tampa, United States

Latest news

Stocktwits

ZacksSCR Nov 3, 6:15 PM
$HURA Potential Population Expansion in IFx-2.0 Phase III Trial https://scr.zacks.com/news/news-details/2026/HURA-First-Look-at-IFx-2-0-Deep-Seated-Tumors-note/default.aspx
0 replies
michpetr Nov 3, 4:21 PM
$HURA oh no.... a new official pr.... another drop... time for short players...
0 replies
TuHURA_IR Nov 3, 3:48 PM
$HURA T-cell exhaustion is a major obstacle to cancer immunotherapies working and continuing to work. Myeloid-derived suppressor cells (MDSCs) can create an environment that limits cancer-fighting T cells. Our preclinical bispecific, bifunctional ADC platform is designed to combine DOR inhibition with VISTA targeting on these immune-suppressing cells. The aim is to reduce their suppressive activity and help prevent T-cell exhaustion. We are developing this approach to address acquired resistance, one of the reasons cancer immunotherapies stop working over time.
0 replies
mspacmanbrrr Nov 2, 4:02 PM
$HURA abos time
0 replies
michpetr Nov 2, 3:56 PM
$HURA pump and dump cycle almost complete, back to where we were weeks back... same pattern.. follow official pr, always drops after that
0 replies
TuHURA_IR Nov 2, 3:30 PM
$HURA We identified the Delta Opioid Receptor (DOR) on myeloid-derived suppressor cells (MDSCs) and its central role in their ability to shield cancers from the immune response. That discovery underpins our DOR technology, which has received a U.S. patent covering specified uses of DOR antagonists in cancer, with a term through 2043 before any patent-term extension. We are developing immune-modulating antibody-drug conjugates (ADCs) targeting DOR on these suppressive cells. This work extends our mission of overcoming resistance to cancer immunotherapy, with the platform advancing toward proof of concept in preclinical models of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
1 replies
TuHURA_IR Oct 30, 8:32 PM
$HURA Evaluating IFx-2.0 in deep-seated tumors could expand the patient population the program may ultimately reach. In this Unboxing Biotech clip, James Bianco estimates that approximately 30% of patients with Merkel cell carcinoma have only deep-seated lesions. He explains how our separate Phase 1b/2a study in MCC of unknown primary origin evaluates IFx-2.0 with KEYTRUDA ( $MRK ) in this setting, using interventional radiology to access the tumors. The study can provide additional first-line response data alongside our ongoing randomized Phase 3 program, helping us understand the potential of this approach. https://www.youtube.com/watch?v=vl5dwhBbF8A
0 replies
TuHURA_IR Oct 29, 2:06 PM
$HURA IFx-2.0 is being evaluated through a separate clinical study for patients with advanced or metastatic Merkel cell carcinoma whose tumors are too deep to be reached through the injection approach used in our Phase 3 trial. In this short clip, CEO James Bianco explains how image-guided interventional radiology may allow IFx-2.0 to be delivered directly into these tumors alongside frontline KEYTRUDA ( $MRK ), potentially extending the approach to patients who would otherwise be ineligible for the Phase 3 study. https://www.youtube.com/shorts/S1twF-rjMlM
0 replies